Abstract Number: 2445 • 2019 ACR/ARP Annual Meeting
Enthesitis, Dactylitis, and Axial Disease in Psoriatic Arthritis (PsA): Impact on Patient Quality of Life and Work Productivity
Background/Purpose: PsA is a chronic, inflammatory disease characterised by peripheral arthritis, axial disease, dactylitis, enthesitis and skin and nail psoriasis. The impact of skin and…Abstract Number: 2465 • 2019 ACR/ARP Annual Meeting
Reliability and Validity of the Self‐Administered Comorbidity Questionnaire in Psoriatic Arthritis
Background/Purpose: The Self‐Administered Comorbidity Questionnaire (SCQ) is a self-report questionnaire. It assesses 13 common medical conditions and the impact of comorbidities on functional status (1).…Abstract Number: 2485 • 2019 ACR/ARP Annual Meeting
Red Cell Distribution Width Positively Correlates with Atherosclerotic Cardiovascular Disease Risk Score in Psoriatic Arthritis and Decreases with BDMARD Therapy
Background/Purpose: Red blood cell distribution width (RDW) is a parameter that measures variation in red blood cell size and volume. It is elevated when there…Abstract Number: 2506 • 2019 ACR/ARP Annual Meeting
The ‘Severity of Nail Psoriasis Score’ (SNAPS) Is Feasible, Reliable and Demonstrates Construct Validity Against the mNAPSI in an Observational Cohort of Patients with Psoriatic Arthritis
Background/Purpose: Background: Longitudinal assessment of psoriatic nail dystrophy and its response to treatment is limited outside of research settings due to the complexity of existing…Abstract Number: 2878 • 2019 ACR/ARP Annual Meeting
Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti–Interleukin-23P19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis
Background/Purpose: Tildrakizumab (TIL), a high-affinity anti–interleukin-23p19 monoclonal antibody, is approved for moderate-to-severe plaque psoriasis treatment and is under investigation for PsA. This study evaluated the…Abstract Number: 259 • 2019 ACR/ARP Annual Meeting
Describing Treatment Patterns and Healthcare Costs in Newly Diagnosed Psoriatic Arthritis Patients by Physician Specialty
Background/Purpose: The clinical heterogeneity of psoriatic arthritis (PsA) presents a variety of diagnostic and treatment challenges, which may be reflected in the way different health…Abstract Number: 1004 • 2019 ACR/ARP Annual Meeting
Genetic Ablation of γδTCR Inhibits IL-23-induced Neutrophilia and Attenuates Epidermal Hyperplasia, Synovitis, Onycholysis and Enthesitis Associated with Psoriatic Arthritis
Background/Purpose: γδ T cells are non-conventional lymphocytes that straddle between innate and adaptive immunity. Although γδ T cells have been implicated in psoriatic arthritis, the…Abstract Number: 1203 • 2019 ACR/ARP Annual Meeting
Psychometric Properities of the Patient Related Outcome Measure FACIT-Fatigue in Rheumatic Arthritis and Psoriatic Arthritis: A Literature Review
Background/Purpose: Fatigue is an important patient reported outcome in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) research. FACIT-Fatigue is a 13-item patient reported outcome (PRO)…Abstract Number: 1505 • 2019 ACR/ARP Annual Meeting
Persistence with Etanercept in Patients with Ankylosing Spondylitis or Psoriatic Arthritis in Germany: A Real-World Analysis
Background/Purpose: Ankylosing spondylitis (AS) and psoriatic arthritis (PsA) treatment includes biologics, prescribed on a long-term basis. As persistence data from real-world practice are limited, the…Abstract Number: 1557 • 2019 ACR/ARP Annual Meeting
Secukinumab Effectiveness in 1134 Patients with Psoriatic Arthritis Treated in Routine Clinical Practice in 11 European Countries in the EuroSpA Research Collaboration Network
Background/Purpose: Secukinumab represents a relatively new approach to treating patients with psoriatic arthritis (PsA) and has shown promising results in RCTs. However, there is a…Abstract Number: 2446 • 2019 ACR/ARP Annual Meeting
Gender Differences in Psoriatic Arthritis – Impact on Tumor Necrosis Factor Inhibitors Persistence and Response
Background/Purpose: The impact of gender on tumor necrosis factor inhibitors (TNFi) effectiveness has been poorly studied in Psoriatic Arthritis (PsA) patients. The objective of this…Abstract Number: 2466 • 2019 ACR/ARP Annual Meeting
Evolution of Health-Related Quality of Life in Psoriatic Arthritis Patients
Background/Purpose: Psoriatic arthritis (PsA) is consider a multifaceted disease, with patients reporting lower health-related quality of life (HRQoL). Data of burden of disease is substantial…Abstract Number: 2486 • 2019 ACR/ARP Annual Meeting
Evaluation of Clinical and Functional Parameters by Joint Involvement and Remission in Psoriatic Arthritis
Background/Purpose: Disease activity of psoriatic arthritis (PsA) is affected by many parameters including joint, spinal and skin involvement, enthesitis, dactylitis and pain. According to disease…Abstract Number: 2509 • 2019 ACR/ARP Annual Meeting
Psoriasis Impact on Patient-Reported Outcomes in Psoriatic Arthritis in a Real-World Setting: Results from the APOPSIS Study
Background/Purpose: Psoriatic arthritis (PsA) is a chronic progressive inflammatory arthropathy associated with psoriasis (PsO). PsA places a considerable burden, adversely affecting health-related quality of life…Abstract Number: 2879 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Low-dose IL-2 in Rebuilting Immunity Re-equilibrium of Psoriatic Arthritis Patients
Background/Purpose: Psoriatic arthritis (PsA) is a T lymphocytes-mediated inflammatory condition. Although regulatory T cells (Tregs) isolated from blood and psoriatic skin have been showed a…
- « Previous Page
- 1
- …
- 64
- 65
- 66
- 67
- 68
- …
- 81
- Next Page »